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Dengue virus has four serotypes and is endemic globally in tropical countries. Neither a
specific treatment nor an approved vaccine is available, and correlates of protection are
not established. The standard neutralization assay cannot differentiate between serotype-
specific and serotype cross-reactive antibodies in patients early after infection, leading to
an overestimation of the long-term serotype-specific protection of an antibody response.
It is known that the cross-reactive response in patients is temporary but few studies have
assessed kinetics and potential changes in serum antibody specificity over time. To better
define the specificity of polyclonal antibodies during disease and after recovery, longitudi-
nal samples from patients with primary or secondary DENV-2 infection were collected over
a period of 1 year. We found that serotype cross-reactive antibodies peaked 3 weeks after
infection and subsided within 1 year. Since secondary patients rapidly produced antibod-
ies specific for the virus envelope (E) protein, an E-specific ELISA was superior compared
to a virus particle-specific ELISA to identify patients with secondary infections. Dengue
infection triggered a massive activation and mobilization of both naïve and memory B cells
possibly from lymphoid organs into the blood, providing an explanation for the surge of
circulating plasmablasts and the increase in cross-reactive E protein-specific antibodies.
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INTRODUCTION
An estimated 390 million people per year are infected with dengue,
resulting in 100 million clinically apparent cases. There is no spe-
cific treatment available against dengue and clinical management
of dengue patients is symptomatic. Fluid replacement and careful
monitoring of patients can prevent fatalities in most cases. How-
ever, the efficacy of supportive treatment depends on available
manpower and bed capacities in hospitals, which can become lim-
iting especially during disease outbreaks (1). Therefore, efforts to
develop a dengue vaccine have been ongoing for decades. The
failure of previous attempts may be attributed to a combina-
tion of complications including insufficient attenuation of vaccine
strains, limited knowledge about neutralizing epitopes, the lack of
an immuno-competent animal model, and no defined correlate(s)
of protection. The neutralization assay remains the gold standard
to measure immunity to dengue, even though a correlation with
protection has not been proven in humans (2). It appears dif-
ficult to standardize the assay due to its sensitivity to changes
in temperature, incubation time, and pH (3, 4). Furthermore,
a basic biological problem of the assay is that it cannot distin-
guish between cross-protective immunity and serotype-specific
protective immunity. Epidemiological studies have shown that
herd immunity to a prevalent serotype protects the population
for several years against the serotype of infection but not against
other serotypes (5, 6). On the other hand, an infection with one
serotype confers temporary immunity to all four serotypes, show-
ing that a cross-reactive component of the immune response elicits
temporary tetravalent protection (7–10). On a population level,
the cross-protective effect appeared to last for 1–3 years (11). On
an individual level, experimental infection studies with humans
suggest that cross-protection lasted as long as 9 months (12).
Prospective cohort studies estimated that cross-protection lasted
1.6–2 years, based on the observation that re-infections during
this time window were subclinical (8, 10). None of these studies,
however, provide information about the serum antibody epitopes
during acute disease and later during the period of cross-reactivity.
The coat of dengue virus particles consists of the structural pro-
teins prM and E, which are assembled on a lipid bilayer derived
from the host cell membrane (13). Ninety dimers of the E pro-
tein are arranged in a densely packed repetitive manner to form
the virus particle and the E protein is the only protein exposed on
mature virus particles (13). The E protein has three domains (EDI,
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EDII, EDIII) and antibodies against serotype-specific epitopes of
EDIII have been described to be more potently neutralizing than
Abs against EDI and EDII (14, 15). The pr component is cleaved
during virus maturation, leaving behind the M protein, which
spans the lipid bilayer and is hidden by E proteins. In mosquito
and mammalian cell lines, PrM cleavage is incomplete and part
of the released virus particle is partially or completely immature,
resulting in the display of prM on released virus particle (16). Such
immature virus particles are less infectious than mature virus par-
ticles. However, PrM-specific antibodies in patients may facilitate
Fc-receptor-mediated infection via antibodies bound to prM on
immature virus particles in a process called antibody-dependent
enhancement (ADE) (17, 18). It has been shown that a signifi-
cant fraction of antibodies in serum and antibodies isolated from
immortalized memory B cells from healthy donors with a previ-
ous dengue infection bound to prM, whereas the remainder of the
isolated antibodies bound to non-structural proteins and to the E
protein (17, 19). In contrast to antibodies cloned from memory B
cells, antibodies cloned from plasmablasts during the acute phase
of a secondary infection were almost exclusively EDI or -II specific
(20). There is evidence that the fusion loop of EDII in particular
appears to constitute a major target of serum antibodies (21, 22).
The fusion loop is essential for infection because it allows the virus
to fuse with the host cell membrane in endosomes for the release
of the viral RNA. Only a small percentage of the E protein-specific
memory B cell-derived antibodies in humans were found to bind
to EDIII (14, 19). Moreover, recent reports started to question the
biological relevance of EDIII-binding neutralizing antibodies for
protection (23, 24).
Apart from the study by Lai et al. (22), which addressed the
binding of serum antibodies to two conserved amino acids in
the fusion loop 3–18 months after infection, we are not aware of
studies that characterized epitopes of dengue antibodies in lon-
gitudinal patient blood samples. Such data, however, can help to
better understand the molecular basis of cross-reactivity during
acute disease and in immune memory.
Here, we analyzed longitudinal plasma samples from patients
with PCR-confirmed primary or secondary DENV-2 infection and
tested the neutralizing capacity of plasma antibodies, their abil-
ity to bind to virus particles, to recombinant E protein, and to
recombinant EDIII. We found that E protein-specific antibodies
increased rapidly after infection. In contrast, EDIII-specific anti-
body responses varied substantially between patients and EDIII-
specific titers generally dropped within 7 months after infec-
tion. The EDI and -II protein-specific antibody responses lasted
for 1 year after infection and likely represented cross-protective
immunity.
MATERIALS AND METHODS
PATIENT SAMPLES
As part of the prospective Early Dengue (EDEN) infection and
outcome study in Singapore (25), adult patients (age >21 years)
presenting at community primary care polyclinics with acute onset
fever (>38.5°C for less than 72 h) without rhinitis or clinically
obvious alternative diagnoses, were included in the study. For the
first cohort, a total of six whole blood samples were collected from
each volunteer into EDTA-vacutainer tubes (Becton Dickinson)
at recruitment (acute phase) and subsequently over a period of
1 year after disease onset (Table 1). For the second cohort, a total
of two whole blood samples were collected into EDTA-vacutainer
tubes during the acute phase of the disease and 3–4 months later
(Table 2). Patients were diagnosed by DENV-specific RT-PCR (26)
and by NS1 test (SD Bioline). The commercially available PanBio
Indirect ELISA kit (Inverness Medical, Australia) was used to clas-
sify patients experiencing a secondary infection based on their IgG
seropositivity in the sample collected within 72h after fever onset.
ETHICS STATEMENT
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The research, which involved fever
patients enrolled in the study was approved by the Domain Spe-
cific Review Board of Singapore’s National Healthcare Group
Table 1 | Cohort 1: longitudinal antibody analysis.
Number of
patients
Age; mean
(range)
Sex DENV-specific
IgG <72 h after
fever onset
Serotype of
infection
Number of samples tested
<72 h 4–7 days 15–25 days 4 month 7 month 12 month
14 32.5 (15–56) 4 F, 11 M − DENV-2 13 13 13 14 13 11
12 40.9 (23–65) 4 F, 10 M + DENV-2 12 12 9 11 10 8
Table 2 | Cohort 2: cell phenotype analysis and PB correlations.
Number of
patients
Age; mean
(range)
Sex DENV-specific
IgG <72 h after
fever onset
Serotype of
infection
V1: 4–7 days
(mean 5.39 days)
V2: 4 months
(mean 126 days)
15 36.47 (21–50) 3 F, 12 M – 14 DENV-2, 1 DENV-1 15 15
13 35.77 (21–67) 1 F, 12 M + 12 DENV-2, 1 DENV-1 13 9
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(Domain E) and patients gave written informed consent (DSRB
Refs. B/05/013, 2010/00227, and 2011/01770).
ELISA
Maxisorp plates (Nunc) or half-area plates (Greiner) were used
for all ELISAs. For the detection of virus particle-specific anti-
bodies, ELISA plates were coated with PEG-precipitated and UV-
inactivated DENV serotypes 1–4. For E protein-specific ELISA,
the soluble part of E proteins of DENV1-4 with a His-tag were
produced in S2 cells as described previously (27). For EDIII-
specific ELISA, EDIII of DENV1-4 with a His-tag was produced
in S2 cells, using the strategy described for Yellow Fever Virus in
Ref. (28). Proteins were purified using Ni-beads. Half-area ELISA
plates (Greiner) were coated at 75 ng/well. For all ELISAs, plates
were blocked with PBS, 0.05% Tween 20 (PBST) and 3% skimmed
milk. Sera and a standard containing pooled dengue-IgG positive
plasma were diluted in blocking buffer on the coated plates for
1 h at RT before washing with PBST. Threefold serial dilutions
from 1:200 to 1:48600 were tested. To standardize results between
plates, a positive control was included on every plate and a ratio
was calculated as follows: ratio of sample x= (OD450(sample x)−
OD450(blank))/(OD450(positive control)−OD450(blank)). The ratio of
the positive control is therefore 1 for all ELISA graphs. For clar-
ity, the ratio of only one serum dilution (1:600) per sample and
time point is shown in all Figures. Pooled serum from dengue-
naïve healthy donors was used as a negative control and included
on all plates. Anti-human IgG-HRP (Sigma) was added at a con-
centration of 1:2000 and incubated for 1 h at RT. After washing,
3,3,5,5-tetramethylbenzidine HRP substrate solution (Sigma) was
added. The color reaction was stopped with 1 M HCl.
NEUTRALIZATION ASSAY
For the measurement of neutralization, heat-inactivated plasma
samples, heat-inactivated pooled dengue-naïve plasma as a nega-
tive control and antibody 4G2 as a positive control were serially
diluted in RPMI medium in 96-well plates (serum was diluted
threefold over six wells starting with 1:200, mAb 4G2 starting con-
centration was 5µg/ml) and a constant amount of virus (MOI
0.1–1) was added. The antibody-virus mixtures were incubated at
37°C for 30 min and then 50µl of the mixtures were transferred to
another 96-well plate containing 200,000 U937 cells (ATCC) sta-
bly transfected with human DC-SIGN (MOI 0.1-1) per well. After
2 h of infection, 150µl RPMI medium containing 10% FCS was
added. After incubation over night, the infected cells were fixed
and stained intra-cellularly with 4G2-Alexa 647. The percentage
of infected cells was quantified by flow-cytometry and data were
analyzed with GraphPad Prism software for the calculation of the
50% neutralizing titer (NT50).
CELL LINES AND VIRUS STRAINS
All viruses used were produced in C6/36 mosquito cells
(ATCC). The following patient isolate strains were used: DENV1-
05K2916 [EU081234 (29)], DENV2-TSV01 (30), DENV3-
VN32/96 (EU482459), and DENV4-2641Y08 (isolated by Envi-
ronmental Health Institute, Singapore). DENV3-VN32/96 was
a gift from Dr. Cameron Simmons, Oxford University Clinical
Research Unit, Viet Nam.
FLOW-CYTOMETRY ANALYSIS
White blood cells were isolated from 8 to 10 ml whole blood using
CPT (BD) tubes containing Sodium Citrate as an anti-coagulant.
Cells were counted and one million cells were stained directly
for flow-cytometry analysis or all cells were frozen in RPMI
medium containing 20% FCS and 10% DMSO. Frozen cells were
thawed in batches for flow-cytometry analysis. Antibodies were
purchased from Biolegend, except for anti-CXCR5-biotin (BD
Pharmingen) and anti-CD14-ECD (Beckman Coulter). CXCR5-
biotin was labeled with Streptavidin-APC-Cy7 (Biolegend). Cells
were stained on ice for 30–60 min and washed with FACS buffer
(PBS, 2% FCS, 5 mM EDTA, 0.1% sodium azide). Fixable blue live-
dead marker (Invitrogen) was added freshly to the antibody mix
and was incubated together with the surface marker antibodies.
Cells were washed and fixed with 1% formalin for analysis.
STATISTICAL ANALYSIS
Data were initially analyzed with transMART (31). Data sets found
to be significant were further analyzed with Prism Software (ver-
sion 6 for Mac) and the statistical tests used were indicated in
the figure legends. A p value of <0.05 was considered statistically
significant.
RESULTS
THE ACUTE ANTIBODY RESPONSE IS DOMINATED BY
CROSS-REACTIVE, E PROTEIN-SPECIFIC ANTIBODIES, WHICH
CIRCULATE IN THE BLOOD FOR LESS THAN 1 YEAR
The DENV-neutralizing activity of patient plasma is the average
of binding capacities of a mixture of antibodies with different
specificities. Antibodies binding to E protein epitopes and possi-
bly also to prM epitopes can potentially be neutralizing (4, 32).
With the aim to better define the specificity of polyclonal anti-
bodies during disease and after recovery, longitudinal samples
from 13 patients with primary DENV-2 infection and from 12
patients with secondary DENV-2 infection were collected over a
period of 1 year, with the first blood sample being drawn within
72 h after fever onset (Table 1, Cohort 1). Neutralizing antibod-
ies to all four DENV serotypes were quantified for nine primary
and nine secondary patients with a flow-cytometry-based assay
using U937-DC-SIGN cells. All longitudinal samples per patient
were measured together in the same experiment. Since acute sera
are highly neutralizing the lowest serum dilution used was 1:200
and the assay was not designed to accurately determine NT50
titers below this dilution. Whereas the response to DENV-2 dom-
inated in both primary and secondary patients, cross-reactivity
was observed particularly for the secondary patient group, and
this cross-reactivity lasted for up to 1 year after the infection
(Figure 1A). Cross-neutralizing activity of polyclonal antibodies
is well described (33) and is thought to contribute to protec-
tion in individuals with one or multiple previous infections (9,
34), yet the epitopes of the cross-reactive polyclonal antibodies
during the period of cross-protection are less well defined. We
analyzed the specificity of DENV-binding polyclonal antibodies
in plasma using ELISAs coated either with recombinant E protein
or with PEG-precipitated, UV-inactivated virus particles (UV-
DENV) (Figures 1B,C). As for the neutralization assay, all lon-
gitudinal samples per patient were analyzed together in the same
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FIGURE 1 | More rapid generation of E protein monomer/dimer-specific
Abs compared to virus particle-specific antibodies. Plasma samples from
patients with a primary or a secondary DENV-2 infection were analyzed at the
indicated time points after onset of fever. (A) Neutralizing titers against all
four DENV serotypes were measured. Dashed lines indicate the level of
detection of the assay. Dots represent NT50 geometric means of nine donors
per group. (B,C) ELISA to test binding of plasma antibodies to UV-treated,
PEG-enriched DENV, or to recombinant E protein of DENV-2 (B) and
DENV-1 (C). A one-way ANOVA test was performed. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 indicate titers that were significantly different
from the titers measured within 72 h of fever onset (average day 2). Dashed
lines indicate values for the positive and negative control, respectively.
experiment. An SDS-PAGE analysis of the recombinant DENV-
2 E protein showed two bands, a smaller band for the monomer
(40 kDa) and a less prominent band for the dimer (80 kDa) (Figure
S1 in Supplementary Material). Recombinant E protein can spon-
taneously form dimers via the dimerization domain EDII (35)
and both monomer- and dimer-specific antibodies are possibly
detected in the E ELISA. In contrast to antibodies binding to
recombinant E protein, antibodies binding to UV-DENV particles
can be specific for E protein monomers, dimers, or for quater-
nary structures spanning more than one E dimer (36). We found
that antibody titers to UV-DENV and to E protein both peaked
between day 15 and 25 after onset of fever for the serotype of infec-
tion, DENV-2 (Figure 1B), and that antibodies cross-reacting with
DENV-1 showed a similar kinetics (Figure 1C). Interestingly, titers
against E protein of DENV-2 and DENV-1 increased more rapidly
than titers against UV-DENV-2 and UV-DENV-1 in secondary
patients.
These data showed that cross-reactive antibodies targeted at E
protein increased during acute infection and dropped to almost
baseline within 1 year. The different early kinetics between E- and
UV-DENV-specific titers further suggested that a majority of B
cells secreting antibodies during the acute infection were specific
for the E protein monomer or dimer, and that less B cells seemed
to be specific for complex viral epitopes, which would only be
detected in the UV-DENV ELISA. Similar to the kinetics of the
ELISA, both the specific and cross-reactive neutralizing response
declined within 1 year.
PRE-EXISTING IgG TITERS ARE NOT INDICATIVE OF THE ACUTE
ANTIBODY RESPONSE
Patients were classified as dengue-naïve (primary infection) or
dengue-immune (secondary infection) based on the pre-existing
IgG titer measured in the <72 h sample using the commercially
available PanBio indirect IgG ELISA kit (37). Data obtained with
our in-house E protein ELISAs in Figure 1 showed that titers spe-
cific for E protein increased rapidly between the first (<72 h) and
the second time point (4–7 days). This indicated that the early
anamnestic response would be more accurate than pre-existing
titers to distinguish dengue-naïve from DENV-immune patients
and that the E protein ELISA could be more sensitive than the
UV-DENV ELISA in distinguishing patients with primary or sec-
ondary infections. To test this hypothesis, we compared titers from
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FIGURE 2 | Pre-existing dengue-specific IgG antibodies are not
indicative of the anamnestic IgG response 4–7 days after fever onset.
(A) Plasma samples were sorted according to the UV-DENV-2 titer
measured at <72 h and the values were compared with the E DENV-2
titers at the same time point and with UV-DENV-2 titer measured 4–7 days
after onset of fever. (B) Plasma samples were sorted according to their
UV-DENV-2 titer measured at 4–7 days after onset of fever and compared
with E DENV-2 and E DENV-1 titers at the same time point. Patient IDs in
red indicate secondary infections whereas patient IDs in black indicates
primary infections. The classification primary versus secondary infection
was made based on pre-existing IgG measured with the commercial
indirect PanBio ELISA kit (see Materials and Methods) in samples
collected <72 h after fever onset. *Indicates samples that were not
available.
the two early time points measured with both E- and UV-DENV
ELISA. We first compared OD ratios measured in the UV-DENV
ELISA <72 h after fever onset with E ELISA titers at the same
time point and with UV-DENV ELISA titers measured 4–7 days
after fever onset (Figure 2A). UV-DENV OD ratios measured
<72 h after fever onset did not show a clear cut-off between pri-
mary and secondary patients (as classified based on PanBio kit)
and the samples did not cluster at the 4–7 days time point when
arranged in the same sequence (Figure 2A). In contrast, when
the UV-DENV and E ELISA OD ratio was measured at 4–7 days
(Figure 2B), 11 out of 12 secondary cases (patient ID on x-axis
in red, based on PanBio kit) had significantly higher E ELISA
OD ratios compared to primary cases (patient ID on x-axis in
black, based on PanBio kit). The segregation into primary and
secondary groups was evident for both DENV-2 and DENV-1
E protein ELISA, showing that day 4–7 antibodies were largely
cross-reactive.
In summary, while E and UV ELISA titers were comparable
at the <72 h time point, the E ELISA appeared to be more sen-
sitive than the UV-DENV ELISA in distinguishing primary from
secondary dengue patients when measured at defervescence (4–
7 days after fever onset), in line with the finding that the majority
of the anamnestic response seemed to be specific for E protein
monomers and dimers.
SEROTYPE-SPECIFIC E PROTEIN-, BUT NOT EDIII-SPECIFIC ANTIBODIES
REMAIN ELEVATED FOR AT LEAST 1 YEAR AFTER INFECTION
Several recent publications suggested that EDIII-specific anti-
bodies, although often highly neutralizing and serotype-specific,
are rare in the repertoire of dengue-immune individuals (14,
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38). We assessed whether, despite their low relative abundance,
EDIII-specific antibodies correlated with NT50 or E ELISA titers
in our cohort. No convincing correlations between EDIII titers
and E titers or between EDIII titers and NT50 were observed
(data not shown). Surprisingly, neither primary nor secondary
patients generated a strong long-lasting response against DENV-
2 EDIII, in contrast to the robust DENV-2 E protein-specific
response observed. Patients with a transient DENV-2 EDIII-
specific response were found mostly in the secondary infection
group (Figure 3A). Similarly, a transient DENV-1 EDIII-specific
response was observed in the secondary patient group, and the
samples that were positive for DENV-1 EDIII were also positive for
DENV-2 EDIII (Figure 3B), suggesting that mostly conserved epi-
topes in EDIII accounted for the titers. Interestingly, one primary
patient developed high titers of DENV-1 EDIII-specific antibod-
ies after DENV-2 infection. The response was highly specific for
DENV-1, with no detectable binding to DENV-2 EDIII. Even
though a more sensitive Taqman qRT-PCR (39) was performed
in addition to the SYBR-green based serotype-specific qPCR we
could only detect DENV-2 – and no DENV-1viral RNA in the
plasma of this patient. A potential alternative explanation for the
DENV-1 specific response could be a molecular mimicry of EDIII
with a self-or non-self antigen.
In summary, EDIII-specific serum antibodies were mostly
cross-reactive and did not correlate with E protein-specific anti-
body titers. The EDIII-specific response seemed to vary substan-
tially between patients. The reason for this is unclear, but it is
an important point to consider when studying small numbers of
patient samples.
CROSS-REACTIVE NEUTRALIZING ANTIBODIES CORRELATE WITH
ACUTE E PROTEIN-SPECIFIC ANTIBODIES BUT NOT WITH E
PROTEIN-SPECIFIC ANTIBODIES FROM THE IMMUNE MEMORY PHASE
Since both the E protein-specific titers and NT50 started to increase
as early as 4–7 days after infection (Figure 1) we tested whether
there was a correlation between these two readouts, and whether
the correlation was consistent over time (Figure 4). For DENV-
2, the serotype of infection, a significant correlation between
NT50 and E ELISA titers was first seen 15–25 days after fever
onset and this correlation was consistent for at least 1 year. In
contrast, the correlation between DENV-1 NT50 and DENV-1 E
ELISA was only significant 15–25 days after fever onset and not
for the later time points (Figure 4A). Only NT50 values calcu-
lated from a neutralization curve with a good fit (R2 value) were
included in the analysis. Day 4–7 time point samples were dif-
ficult to analyze in the DENV-1 neutralization assay, even when
starting with a lower serum dilution. As a consequence of this the
correlation for DENV-1 at 4–7 days did not contain enough data
points for interpretation and was only included for the sake of
completeness (Figure 4B). However, we could conclude that dur-
ing early convalescence (15–25 days), E protein-specific DENV-1/2
cross-neutralizing antibodies were likely responsible for the signif-
icant correlation between NT50 and ELISA for both homologous
and heterologous serotypes. At late time points DENV-1 cross-
neutralizing activity and DENV-1 “cross-binding” ELISA titers
appeared to decline with different kinetics, resulting in a low
correlation between DENV-1 NT50 and DENV-1 ELISA. The
FIGURE 3 |The EDIII-specific antibody titers vary substantially
between patients and are not long-lasting. Plasma samples from
patients with primary or secondary infection were analyzed for binding to E
and EDIII protein and each patient’s antibody binding profile is shown
individually by connected symbols. The mean values for the same data are
shown in Figures 1B,C. (A) Individual curves for binding to DENV-2 E and
EDIII protein. (B) Individual curves for binding to DENV-1 E and EDIII
protein. The dashed lines indicate values for pooled neg. and positive
control plasma, respectively. Mouse mAb 3H5 was used as a positive
control for the DENV-2 EDIII ELISA because the pooled positive plasma did
not show more binding to DENV-2 EDIII than the pooled negative plasma.
The use of a different positive controls for DENV-1 and DENV-2 resulted in
OD ratios of a different scale for the two EDIII ELISAs.
correlation in Figures 4A,B included both primary and secondary
patients because the number of samples was too small to analyze
the two groups separately. To address different correlation out-
comes for primary and secondary patient due to different levels of
cross-reactivity we compared E ELISA titers measured at the most
cross-reactive time point (15–25 days) with E ELISA titers mea-
sured at later time points (Figure 4C). Primary patients showed a
consistently high correlation between DENV-2 E protein-specific
antibodies measured at day 15–25 and DENV-2 E protein-specific
Frontiers in Immunology | Immunological Memory August 2014 | Volume 5 | Article 388 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toh et al. Dengue cross-reactive immune memory
FIGURE 4 | Long-term correlation between E protein binding and NT50
for the serotype of infection. Correlations of E protein- and
UV-DENV-ELISA titers with NT50 for plasma from primary and secondary
patients were calculated individually for the indicated time points of
disease. (A) Spearman R for the correlations between NT50 and ELISA
titers are shown for each time point. (B) Graphs illustrating the data points
used for the calculations of Spearman R shown in (A). Correlations for
DENV-2 specific antibodies are shown in the graphs on the left and
correlations for DENV-1 specific antibodies are shown in the graphs on the
right. (C) Correlations between the highly cross-reactive E protein ELISA
titer measured at day 15–25 for DENV-2 and the DENV-2 and DENV-1 E
protein ELISA titers measured at time points indicated in the x axis were
calculated. The correlations were calculated separately for primary and for
secondary patients.
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antibodies measured at later time points, and the correlation
between DENV-2 E protein-specific antibodies measured at day
15–25 and DENV-1 E protein-specific antibodies at later time
points was only slightly less consistent. In contrast, secondary
patients’ DENV-2 E-specific antibodies measured at day 15–25
did not correlate with DENV-2 and DENV-1 E-specific antibodies
measured at late time points (Figure 4C). We concluded that while
the cross-reactivity correlations were markedly different between
primary and secondary patients the readouts for DENV-2 and
DENV-1 ELISAs were similar, suggesting that the different corre-
lations associated with DENV-2 and DENV-1 reactivity observed
in Figure 4A were a consequence of changes in the NT50.
In summary, the anti-E protein antibody response in primary
patients measured 20 days to 4 months after infection correlated
with the response measured 1 year after infection. In contrast,
the response in secondary patients measured 20 days after infec-
tion was not predictive of the outcome measured 1 year later,
suggesting that the E protein-specific cross-reactive antibody
response waned within 1 year and that the response became more
serotype-specific within this time frame. Correlations of NT50
and ELISA data might be useful to assess serotype-specific and
cross-protective immunity as early as 4 months after infection
(Figure 4A). However, since the patient cohort analyzed here only
included DENV-2 infected patients, it will be important to test
whether a similar correlation can be observed in a cohort with
different serotypes of previous and new infection.
BOTH NAÏVE AND MEMORY B CELLS ARE ACTIVATED AFTER DENV
INFECTION AND CONTRIBUTE TO THE CROSS-REACTIVE ANTIBODY
RESPONSE
We next tested, which B cells could account for the rapid increase
in DENV-specific antibody titers. Since primary patients do not
have memory B cells specific for dengue we assumed that more
naive B cells would be activated in primary patients compared
to secondary patients, and that the higher antibody titers in sec-
ondary patients would be contributed mostly by memory B cells
since memory B cells differentiate into plasmablasts more effi-
ciently than naïve B cells (40). We analyzed blood B cells from
patients during acute disease (between day 4–7 after fever onset,
visit 1) and 3–4 months later (visit 2) by flow-cytometry and mea-
sured changes in absolute numbers for naïve B cells, memory B
cells and plasmablasts (Table 2, Cohort 2 and Figure 5A). As
FIGURE 5 | Systemic mobilization of naïve and memory B cell both
during primary and secondary infection. (A) PBMCs from patients in
the second cohort (Table 2) collected 4–7 days and 4 months after fever
onset were stained for flow-cytometry analysis. Cells in the graphs were
gated on live and CD14-negative cells. CD38 and CD27 expression on
CD19+/low cells was then used to differentiate between memory B cells
(MBC), naïve B cells, and plasmablasts (PB). Graphs from one
representative patient are shown. (B) Quantification of the cell subsets
illustrated in (A). (C) Data in (B) were separated into patient groups
experiencing a primary or secondary infection. (D) Correlation between
PB numbers detected at v1 and UV-DENV ELISA OD ratio (OD450/
ODpos.control) measured at v1 and v2. (B–D) Each dot represents one
patient; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (Wilcoxon
matched-pairs signed rank test).
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reported previously by us and by others, a significantly higher
number of plasmablasts was detected during visit 1 compared
to visit 2, and the number of white blood cells in dengue cases
was significantly lower during visit 1 compared to visit 2 (41,
42) (Figure 5B). In the acute phase we also observed a signifi-
cant drop in memory B cell numbers, one hypothesis for which
is that a majority of memory B cells had differentiated into plas-
mablasts (Figures 5A,B). Interestingly, decreased memory B cell
numbers during acute disease were observed for both primary
and secondary patients (Figure 5C), suggesting that a large pro-
portion of the activated memory B cells were not DENV-specific.
To address whether re-activated memory B cells during sec-
ondary infection accounted for long-lasting DENV-specific titers,
we compared plasmablast numbers during acute disease with titers
measured 4 month after infection (Figure 5D). While a weak
correlation existed between plasmablast numbers and DENV-
specific titers for secondary patients during acute disease and
4 months after infection, no such correlation was observed for
primary cases. This finding indicated that primary infection plas-
mablasts were activated as “bystanders” and that the number of
plasmablasts did not correlate with DENV-specific titers at a later
time point.
Fas-receptor (CD95) was significantly up-regulated on both
naïve and memory B cells at visit 1 compared to visit 2, exposing
the cells to Fas-mediated killing (Figures 6A,B). Loss of CXCR5
and up-regulation of CD95 occurred in parallel, suggesting that
the majority of activated B cells did not home back to lymphoid
tissues and were prone to die (Figure 6A).
Taken together, dengue infection seemed to systemically acti-
vate both naïve and memory B cells based on the increase in
FIGURE 6 | Up-regulation of Fas-ligand (CD95) on memory and naïve
B cells during acute disease indicates differentiation to
plasmablasts (PB) and impending cell death. PMBCs shown in
Figure 5 were stained for CXCR5 and CD95 and the expression of these
markers was analyzed on MBCs, naïve B cells, and PBs, including all 28
patients of cohort 2 regardless of primary or secondary infection.
(A) Gating of CXCR5 and CD95-expressing cells during v1 and v2 for one
representative patient. (B) Quantification of the percentages of CD95+
cells gated as illustrated in (A). ***p<0.001 (Wilcoxon matched-pairs
signed rank test)
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CD95-expressing cells and based on the reduction in total cell
numbers for both populations.
DISCUSSION
Longitudinal analysis of antibody specificities and flow-
cytometry-based analysis of B cell activation and mobilization
revealed the following key characteristics of the DENV-specific
humoral response: (i) the anamnestic response in secondary
patients was highly dominated by cross-reactive E protein
monomer- or dimer-specific antibodies and this response clearly
differentiated secondary from primary patients. (ii) The E protein-
specific, DENV serotype cross-reactive antibody response sub-
sided within 1 year after infection.
Titers to EDIII remained low in primary patients and were vari-
able in secondary patients throughout the time period assessed.
In contrast, B cells specific for EDI/II seemed to be activated
efficiently in both primary and secondary patients (Figure 3).
Furthermore, the increase in UV-DENV-specific titers was less sig-
nificant compared to the increase in EDI/II-specific titers during
acute disease in secondary patients (Figure 1). Two studies recently
described highly neutralizing antibodies with footprints spanning
the EDI-EDII hinge region and EDIII of two adjacent E proteins
on virus particles (36, 43). Additionally, the EDI/II hinge-region
was found to elicit serotype-specific immune memory: a “serotype
swop” of hinge region amino acids was sufficient to abrogate neu-
tralizing activity by up to 80% and the neutralizing activity of sera
from animals immunized with “hinge-region-chimeric” viruses
was specific to the serotype of the hinge region (44). While we
found that complex epitope-specific antibodies that only bound
to virus particles seemed to be less abundant than E protein
monomer/dimer-specific antibodies during the acute response,
cross-reactive hinge region-specific antibodies binding to E pro-
tein monomer/dimers could be responsible for the increasingly
serotype-specific response at later time points (Figure 4).
Memory B cells do not actively secrete antibodies and, unlike
long-lived plasma cells, do not contribute to the serum antibody
repertoire after recovery. However, memory B cells can be effi-
ciently activated after a re-exposure to dengue virus. The data
presented here suggest that memory B cells specific for con-
served regions of EDI/II were activated abundantly, whereas this
did not seem to occur for B cells specific for conserved regions
of EDIII. It will be important for vaccine design to under-
stand the mechanisms that drive such selective memory B cell
re-activation.
During the analysis, we realized that it can be difficult to define
true primary, DENV-naïve patients in a dengue endemic region.
Pre-existing antibodies did not seem to be a good indicator, par-
ticularly in cases where the infection occurred a long time ago and
where circulating DENV-specific antibodies may have waned over
many years. Despite the absence of circulating antibodies, DENV-
specific memory cells can still remain in the lymphatic organs and
can be re-activated and expanded after infection, resulting in a
rapid and high production of antibodies. Since secondary DENV
infection is associated with a higher risk of developing a severe
disease, an unambiguous test that is able to distinguish primary
from secondary infection could be useful for clinicians to assess a
patient based on a combination of warning signs of severe disease
(2) and pre-existing immunity. Furthermore, a clear distinction
between primary and secondary infection is important for dengue
vaccine trials, since safety may have to be addressed separately in
dengue-immune and dengue-naïve individuals. Drug trials may
also benefit from an unambiguous distinction between primary
and secondary patients since the kinetics and magnitude of viremia
and NS1-positivity, which are used as readouts for efficacy, may
differ between the two patient groups (45).
We suggest that E protein-specific antibodies measured at day
4–7 after fever onset are a sensitive biomarker to distinguish
primary from secondary patients.
Besides this, cross-reactive antibodies produced during acute
infection are relevant for protection. Human challenge exper-
iments and epidemiological studies have shown that serotype
cross-reactive responses contribute to protection (9, 12, 34). How-
ever, the cross-protection is temporary and it is important to
understand at which time point the response becomes serotype-
specific. Based on our results and results from other studies (33),
the recommendation for vaccine testing would be to measure
titers only 1 year after immunization to assess serotype-specific
responses. Alternatively, the combined analysis of NT50 and E
ELISA (Figure 4A) could potentially be useful to define serotype-
specific immunity as early as 4 months after infection (Figure 4A).
It would be interesting to test this correlation in other cohorts with
different serotypes of infection.
The reason for the massive activation of B cells during acute
dengue infection that seems to account for the cross-reactive
response remains unclear. Specific activation of B cells by virus
particles binding to the B cell receptor and unspecific activa-
tion via cytokines possibly act together (46). Recent evidence
suggests that cytokines produced by CD14+CD16+ monocytes
contribute to plasmablast formation in dengue patients (47). We
show that both naïve and memory B cells were activated in pri-
mary and secondary patients based on CD95 expression, pointing
to a substantial unspecific activation of B cells. It is remarkable
that, despite the apparent unspecific B cell activation, a large pro-
portion of plasmablast-derived antibodies in secondary patients
bind to DENV (7, 20, 42, 48).
Previous studies defined the fusion loop of EDII as a major
antibody target and reported that concentrations of antibodies
binding to fusion loop amino acids W101 and F108 remained con-
stant over 18 months after infection (22). The reason for the high
immunogenicity of the fusion loop remains unclear. We detected
decreasing E protein-specific titers over 12 months, which suggests
that the fusion loop is only one of several epitopes in the E protein
that accounts for cross-reactivity.
Plasma samples collected during acute secondary infection
bound efficiently to recombinant E protein and less to virus par-
ticles. In contrast, steady state plasma samples collected <72 h
or >7 months after fever onset contained antibodies that bound
equally well to recombinant E protein and virus particles, there-
fore, likely representing a more diverse pool of antibodies. The
results from this study suggest that EDII-specific cross-reactive
antibodies were generated during the acute response and were
mostly derived from re-activated memory B cells, whereas anti-
bodies found in the plasma during long-term memory seemed
to be more diverse. These findings can help to better understand
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differences in antibody specificities between the acute response
and immune memory after dengue infection.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00388/
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